Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety...

Area of Science:

• Allergen immunotherapy
• Recombinant allergen preparations
• Immunology

Background:

• Allergen-specific immunotherapy (SIT) using native extracts and allergoids is established.
• Recombinant allergen preparations offer a promising alternative for SIT.

Purpose of the Study:

• To evaluate the dose-ranging safety of subcutaneous immunotherapy (SCIT) using a mixture of five recombinant grass pollen allergens.
• To assess safety in patients with allergic rhinoconjunctivitis, with or without asthma.

Main Methods:

• A randomized, double-blind, placebo-controlled, dose-ranging safety study.
• 50 patients received placebo or 20, 40, 80, or 120 μg of recombinant grass pollen protein.
• Primary endpoint: systemic reactions; Secondary endpoints: skin tests, provocation tests, IgE/IgG levels.

Main Results:

• Eight out of 50 patients experienced mild systemic reactions (grade 1 or 2).
• No severe systemic reactions (grade 3 or 4) were observed across all dosage groups.
• Secondary endpoints indicated potential efficacy and immunological effects of the study medication.

Conclusions:

• The first double-blind, placebo-controlled, subcutaneous immunotherapy, dose-ranging trial with a recombinant Phleum allergen mixture demonstrated a favorable safety profile.
• High doses (up to 120 μg) of the recombinant allergen mixture were well-tolerated in patients with rhinoconjunctivitis.
• This suggests the potential for effective and safe treatment of grass pollen allergies using recombinant allergens.